China’s Biopharma Firm Gan & Lee Teams Up With Novartis In Global Insulin Push

Login to View

Gan & Lee Pharmaceuticals, a biopharmaceutical company specializing in insulin and insulin analogues in China, announced that it has entered into an agreement to commercialize three insulin analogs to Sandoz, a division of Swiss drugmaker Novartis with a focus on biosimilar pharmaceuticals.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in

China Money Network Subscription